Incannex Healthcare Receives FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea
Key Insights
Incannex Healthcare Inc (search). announced that the FDA has granted Fast Track designation for IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (search) treatment.
The designation was supported by promising Phase 2 "RePOSA" study results showing statistically significant reductions in Apnea-Hypopnea Index, with individual reductions of up to 83%.
Fast Track status provides expedited regulatory pathways including more frequent FDA interactions, rolling review eligibility, and potential access to Accelerated Approval and Priority Review.
Incannex Healthcare Inc (search). announced on December 3, 2025, that the U.S. Food and Drug Administration has granted Fast Track designation for IHL-42X, the company's oral fixed-dose combination product candidate for treating obstructive sleep apnea (search) (OSA). The designation represents a significant regulatory milestone for the clinical-stage biopharmaceutical company developing innovative combination therapies.
Clinical Evidence Supporting Fast Track Designation
The Fast Track designation was supported by promising safety, efficacy, and pharmacokinetic results from three clinical trials completed within the IHL-42X development program. The company's successful Phase 2 "RePOSA" study demonstrated statistically significant reductions in Apnea-Hypopnea Index (AHI), with individual reductions of up to 83%, alongside outstanding patient-reported outcomes and an excellent safety profile.
IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea (search). The combination approach represents a novel therapeutic strategy for a condition that currently lacks approved oral pharmacotherapy options.
Regulatory Benefits and Development Pathway
Under the Fast Track program, IHL-42X will benefit from several regulatory advantages designed to expedite development. These include more frequent, structured interactions between Incannex and the FDA to discuss clinical strategy, trial design, and data requirements. The designation also provides eligibility for rolling review, enabling the company to submit completed sections of a future New Drug Application ahead of the full submission.
Additionally, IHL-42X gains potential access to Accelerated Approval and Priority Review pathways, should relevant criteria be met. Incannex expects to receive detailed written feedback from the FDA in response to its Phase 2 data package and clinical development strategy.
Addressing Unmet Medical Need
Fast Track designation is granted by the FDA to drug candidates that treat serious conditions and address unmet medical needs, with the aim of making important new therapies available to patients sooner. OSA affects millions of people globally, yet no approved oral pharmacotherapy currently exists for the condition.
"OSA is a serious disease with impacts on both short- and long-term aspects of patient health and quality of life," said Mark Bleackley, Chief Scientific Officer at Incannex. "We are delighted with the FDA's decision to grant Fast Track designation to IHL-42X for OSA. This supports the potential for IHL-42X to address the unmet need for an oral pharmacotherapy for OSA patients."
Company Leadership Perspective
Joel Latham, President & CEO of Incannex, emphasized the significance of this regulatory milestone: "We believe Fast Track designation for IHL-42X is one of the most significant regulatory milestones in Incannex's history. Following our exceptional Phase 2 results, this designation validates the strength of our data package and the potential for IHL-42X to transform the treatment landscape."
Latham noted that the designation provides a clear, expedited regulatory pathway, allowing the company to accelerate development and capitalize on the foundations built throughout the year, including their recent Nasdaq extension. The company looks forward to working closely with the FDA as they advance IHL-42X toward late-stage development.
About Incannex's Pipeline
Incannex is developing combination medicines that target underlying biological pathways associated with chronic conditions, including obstructive sleep apnea (search), rheumatoid arthritis (search), and generalized anxiety disorder (search). The company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations.
Beyond IHL-42X, the company's pipeline includes IHL-675A, an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate in Phase 2 development for inflammatory conditions such as rheumatoid arthritis (search), and PSX-001, an oral synthetic psilocybin treatment approved for Phase 2 clinical development for generalized anxiety disorder (search).